Glenmark Generics in Argentina – combating cancer for a healthier future

Glenmark Generics Argentina is the hub for generic research, manufacturing and distribution of oncology products for the whole world. This process started with the acquisition of an Argentine oncology company, Servycal S.A. in 2005 by Glenmark. The company’s continuous growth since then now spans 23 countries.  Our team of qualified professionals, pharmacists and physicians has helped position the company as an important player in oncology in Latin and Central America. This process continues, as the company looks to become a global leader in oncology in the future.  Our people, our stringent quality standards and our vision for a healthier world explain the substantial growth Glenmark Generics has experienced in a short time. It has also helped position us as a specialist in cancer care.  

Solutions for a growing problem – The incidence of cancer in the world

Oncology is a specific area which has a major share of the public tender market in most of the countries serviced by Glenmark Generics. The public spending on oncology constitute to around 60% of the total oncology market in most of the developing markets. Cancer as a disease process has had a huge rise in incidence in the last decade. The rise of incidence has been attributed not only to the changing lifestyles of the population across the globe but also to the increasing access to public healthcare. 

The portfolio of Glenmark covers a wide range of generic oncology products which cater to around 75% of all cancers. In the first half of 2007 alone, the company has done 44 launches across 10 markets.